5-Amino-1MQvsTirzepatide

5-Amino-1MQ is a selective inhibitor of nicotinamide N-methyltransferase (NNMT), a cytoplasmic enzyme that is significantly overexpressed in white adipose tissue of obese individuals. NNMT catalyzes the methylation of nicotinamide (a form of vitamin B3) using S-adenosyl methionine (SAM) as the methyl donor, producing 1-methylnicotinamide and S-adenosyl homocysteine. This reaction effectively depletes two critical metabolic cofactors — NAD+ precursors and SAM — from fat cells.

By inhibiting NNMT, 5-Amino-1MQ preserves the cellular pools of both nicotinamide (which feeds NAD+ biosynthesis via the salvage pathway) and SAM (the universal methyl donor required for hundreds of methylation reactions). Increased NAD+ availability activates sirtuin enzymes (particularly SIRT1 and SIRT3), which are master regulators of cellular metabolism — they deacetylate and activate PGC-1alpha (promoting mitochondrial biogenesis), enhance fatty acid oxidation, and suppress lipogenic gene expression. The net effect is that adipocytes shift from a fat-storing to a fat-burning metabolic state.

In preclinical models, NNMT inhibition reduced adipocyte size, decreased total body fat mass, and increased energy expenditure without affecting food intake — suggesting the weight loss mechanism is primarily metabolic rather than appetite-driven. Additionally, NNMT inhibition has shown improvements in insulin sensitivity and reductions in plasma cholesterol. However, all published efficacy data comes from cell culture and rodent studies; no human clinical trials have been completed, so the translational relevance remains uncertain.

Tirzepatide is the first approved dual incretin receptor agonist, simultaneously activating both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. This dual mechanism represents a paradigm shift in obesity and diabetes treatment because the two receptor systems produce complementary and additive metabolic effects that neither achieves alone.

The GLP-1 receptor component works similarly to semaglutide — suppressing appetite through hypothalamic signaling, slowing gastric emptying, and stimulating glucose-dependent insulin secretion. However, the addition of GIP receptor agonism provides unique benefits. GIP receptors in adipose tissue enhance lipid metabolism and may improve fat storage efficiency, while GIP signaling in the brain appears to amplify the appetite-suppressing effects of GLP-1 through distinct neuronal circuits in the hypothalamus.

At the pancreatic level, the dual stimulation of both GIP and GLP-1 receptors on beta cells produces a more robust insulin secretory response than either pathway alone. Tirzepatide also improves insulin sensitivity in peripheral tissues, reduces hepatic fat content, and lowers triglyceride levels. The molecule is built on a modified GIP peptide backbone with GLP-1 receptor cross-reactivity, attached to a C20 fatty di-acid moiety that enables albumin binding and weekly dosing. Clinical trials have shown weight loss of up to 22.5% of body weight, surpassing GLP-1-only agents.